Anemia in chronic kidney disease: causes, diagnosis, treatment.
Most patients with chronic kidney disease eventually become anemic. We should view the management of anemia in these patients as part of the overall management of the many clinically relevant manifestations of chronic kidney disease. Erythropoiesis-stimulating agents (ESAs) are safe and should be used, as treating anemia may forestall some of the target-organ damage of chronic kidney disease.
Nurko
Saul
S
EPO Clinic, Department of Nephrology and Hypertension, The Cleveland Clinic Foundation, OH 44195, USA.
D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy / Q000209:etiology; D002908:Chronic Disease; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007501:Iron / Q000378:metabolism / Q000627:therapeutic use; D007674:Kidney Diseases / Q000150:complications / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D006435:Renal Dialysis
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D000068817:Epoetin Alfa; D007501:Iron